



MISS CELINE BUREL (Orcid ID : 0000-0002-9645-5039)

Article type : Clinical Article

CLINICAL ARTICLE

Management of gestational diabetes in women with a concurrent Sars-Cov-2 infection, experience of a single center in Northern Italy

D'Ambrosi F¹ (0000-0002-5130-2266), Rossi G¹, Soldavini CM¹, Maggi V¹, Cetera GE¹, Carbone IF¹, Di Martino D¹, Di Maso M³ (0000-0002-6481-990X), Ferrazzi E^{1,2}.

¹ Department of Woman, Child and Neonate, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

²Department of Clinical Sciences and Community Health, University of Milan, Milan, EU, Italy.

³Department of Clinical Sciences and Community Health, Branch of Medical Statistics, Biometry and Epidemiology "G.A. Maccacaro", Università degli Studi di Milano

Address for Correspondence:

Francesco D'Ambrosi.

Department of Woman, Child and Neonate, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

mail: dambrosifr@gmail.com;

phone: 00393334932470; fax: 00390270633611

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/IJGO.13434](https://doi.org/10.1002/IJGO.13434)

This article is protected by copyright. All rights reserved

Keywords: Gestational diabetes, COVID-19, management, diet, insulin, pandemic, northern-Italy, IADPSG.

Synopsis: Our management of pregnancies complicated by COVID-19 and gestational diabetes ensures a good maternal and fetal outcome.

Abstract

Objective: In this study we describe the management of women with gestational diabetes (GD) and an ongoing Sars-Cov-2 infection. The aim of the study is to evaluate whether the COVID-19 infection can further complicate pregnancies and thus if the protocol we usually use for GDM pregnancies is also applicable to patients who have contracted a Sars-Cov-2 infection.

Methods: This is a retrospective study analysing all pregnant women with gestational diabetes and a concomitant COVID-19 infection admitted to our Institution for antenatal care between March 1st and April 30th 2020.

Results: Among pregnant women with GD and a concomitant COVID-19 infection, the mean age was 32,9 (SD 5,6) years. Two patients (33%) were of Caucasian ethnicity while four (67%) were non-Caucasian. All patients were diagnosed with COVID-19 during the third trimester of pregnancy. Two women were asymptomatic while four were symptomatic. Only two patients (33,3%) received treatment with insulin. None of the patients required intensive care or mechanical ventilation. No complications were found among the newborns.

Conclusion: the COVID-19 infection was not found to worsen the prognosis of GD patients or of their offspring. Glycaemic monitoring, diet therapy and insulin, when needed, are sufficient for a good metabolic control and a favourable maternal and fetal outcome.

INTRODUCTION

The SARS-CoV-2 pandemic has had a profound impact on health services worldwide, including antenatal care. In Northern Italy, one of the first areas in Europe to be hit by the pandemic, the virus has spread significantly amongst the pregnant population [1]. Repercussions on antenatal care, especially that of high-risk pregnancies, are yet to be analysed [1-3].

Amongst women with high-risk pregnancies, those with gestational diabetes (GD) represent one of the largest sub-groups [4-5]. The prevalence of GD is estimated at around 18% of pregnancies [4].

As far as its repercussions on pregnancy are concerned, GD increases the risk of maternal and perinatal complications, both in the short term and in the long-term, including a higher prevalence of type 2 diabetes in mothers and a greater likelihood of childhood obesity in the offspring [4-5].

As of 2020, COVID-19 can be classified as a complication of pregnancy, especially in women with co-morbidities such as GD [4-8].

In this study we provide a detailed description of the management of the pregnant women with GD and an ongoing Sars-Cov-2 infection who gave birth in our Obstetric Unit, the largest high-risk Maternity Unit in the metropolitan area of Milan, Lombardy.

MATERIALS AND METHODS

This retrospective single centre study was carried out in our Institution Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy, one of the six COVID-19 maternity hubs designed by the Regional Health Authority, between March 1st and April 30th 2020.

All pregnant women with GD and a concomitant COVID-19 infection admitted to our Institution for antenatal care were eligible for the present study.

Sars-Cov-2 infection was diagnosed by the means of a nasopharyngeal swab, which in accordance to the Italian National Guidelines [9] is administered to all women, both symptomatic and asymptomatic, at time of admission.

Screening for GD was carried out according to the International Association of Diabetes and Pregnancy Study Groups' (IADPSG) recommendations [8]. During the first trimester, fasting plasma glucose was dosed. Pre-gestational diabetes (DM) was diagnosed when

fasting glucose levels were ≥ 126 mg/dL (7.0 mmol/L). Women with fasting plasma glucose ≥ 92 mg/dL (5.1 mmol/L) and < 126 mg/dL (7.0 mmol/L) were diagnosed with 1st trimester GDM. Between 24 and 28 weeks of gestation, all women excluding those with DM and 1st trimester GDM, underwent a 75-g oral glucose tolerance test (OGTT) following 72 hours of no dietary restrictions and 10 hours of overnight fast. Plasma glucose levels were measured before, 1 hour and 2 hours after the administration of a 75-g glucose solution. Second trimester GDM was diagnosed according to the IADPSG's criteria as follows: when fasting glucose was ≥ 92 mg/dL (5.1 mmol/L) and/or glucose levels were ≥ 180 mg/dL (10.0 mmol/L) 1 hour after the administration of the glucose solution and/or when glucose levels were ≥ 153 mg/dL (8.5 mmol/L) 2 hours after the administration of the solution.

Initial treatment consisted in a diet prescribed by a nutritionist. Women were asked to fill in a daily blood sugar chart. Insulin therapy was introduced when basal and post-prandial plasma glucose levels exceeded 95 and 120 mg/dl respectively, or 90 and 110 mg/dl when the fetal abdominal circumference exceeded the 75 centile of local reference values [10].

Data was collected from electronic clinical records.

All patients signed an informed consent to use their data anonymously for research purposes.

The study was approved by the Institutional Review Board of Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy (No.1512; date: April 2020).

Statistical analysis

We performed a descriptive analysis of variables and continuous variables are reported in terms of mean and standard deviation (SD). Data was analysed using the statistical package IBM SPSS 22.0 (New York, USA) and Excel for Windows 2010 (Microsoft Corp., Redmond, WA, USA).

RESULTS

More than half of the patients admitted to our Institution between March 1st and April 30th 2020 (51.1%) were aged 35 years and above. 80.3% were of Caucasian ethnicity. 144

(16%) were diagnosed with GD. 50 (5.6%) were tested positive for COVID-19 and, amongst these, 6 (12%) had GD.

The characteristics of the women with GD and a concomitant COVID-19 infection were the following, as shown in table 1. The mean age was 32,9 (SD 5,6) years. 2 patients (33%) were of Caucasian ethnicity while 4 (67%) were non-Caucasian. All patients were diagnosed with COVID-19 during the third trimester of pregnancy. 2 were asymptomatic while the other 4 were symptomatic. Only 2 patients (33,3%) received treatment with insulin. In all cases, due to the coexistence of two risk factors for the pregnancy's outcome (GD and COVID-19 infection), induction of labour or an elective caesarean section were preferred to spontaneous onset of labour. Among these patients, no complications were observed in childbirth. Only one woman required hospitalization for more than 7 days and this was due to the fact that her household was not deemed an adequate setting for her to quarantine. None of the patients required intensive care or mechanical ventilation. No complications were found in the newborns, who were all allowed to room-in with their mothers.

DISCUSSION

Incidence of COVID-19 disease was not greater among the GD population. Moreover, the infection was not found to worsen the prognosis of GD patients or of their offspring. None of the women with GD and a concomitant Sars-Cov-2 infection required hospitalization in an intensive care unit or mechanical ventilation.

Monitoring of glycaemic control and fetal growth, according to the protocols of our Institution, prevented the onset of pregnancy complications.

A possible limitation of the present analysis may be represented by the exiguous number of cases analysed. We expect to increase our study sample in the following months and thus provide further results. The main strength of this study is that it was conducted in one of the six reference centres for the treatment of COVID-19 in women in Lombardy, the first region to be affected by the disease in Europe and one of the areas with the highest diffusion rate of infection [1-10].

In conclusion, glycaemic monitoring, diet therapy and insulin, when needed, are sufficient for obtaining good metabolic control and a favourable maternal and foetal outcome even amongst women with GD and a concomitant Sars-Cov-2 infection.

AUTHOR CONTRIBUTIONS

All authors contributed significantly to the conception, planning, carrying out and analysis of the manuscript. FD, GR and EF were the primary writers of the manuscript. All authors read, revised and consented to the publication of the final manuscript.

CONFLICTS OF INTEREST

None declared. Completed disclosure of interests form available to view online as supporting information.

REFERENCES

1. Ferrazzi E, Frigerio L, Savasi V, et al. Vaginal delivery in SARS-CoV-2-infected pregnant women in Northern Italy: a retrospective analysis [published online ahead of print, 2020 Apr 27]. *BJOG*. 2020;10.1111/1471-0528.16278. doi:10.1111/1471-0528.16278.
2. Thangaratinam S, Cooray SD, Sukumar N, et al. Endocrinology in time of Covid-19: Diagnosis and management of gestational diabetes mellitus. *Eur J Endocrinol*. 2020;183:G49-G56. doi:10.1530/EJE-20-0401
3. Gao YJ, Ye L, Zhang JS, et al. Clinical features and outcomes of pregnant women with COVID-19: a systematic review and meta-analysis. *BMC Infect Dis*. 2020;20(1):564. Published 2020 Aug 3. doi:10.1186/s12879-020-05274-2
4. Karli Mayo, MD; Nir Melamed, MD; Hilde Vandenberghe, PhD, FCACB, DABCC; Howard Berger, MD. The impact of adoption of the International Association of Diabetes in Pregnancy Study Group criteria for the screening and diagnosis of gestational diabetes. *Am J Obstet Gynecol*. 2015 Feb;212:224.e1-9. doi: 10.1016/j.ajog.2014.08.027. Epub 2014 Aug 27.
5. D'Ambrosi F, Rossi G, Soldavini CM, et al. Ultrasound assessment of maternal adipose tissue during 1st trimester screening for aneuploidies and risk of

developing gestational diabetes. *Acta Obstet Gynecol Scand.* 2020;99:644-650.
doi:10.1111/aogs.13800

6. Michie S, West R & Amlôt R. Slowing down the covid-19 outbreak: changing behaviour by understanding it. *BMJ Opinion*, March 11th 2020.
7. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet* 2020; 395: 809-15.
8. International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care* 2010;33:676–682.
9. <http://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2020&codLeg=73669&parte=1%20&serie=null>
10. Rossi G, Somigliana E, Moschetta M, Bottani B, Barbieri M, Vignali M. Adequate timing of fetal ultrasound to guide metabolic therapy in mild gestational diabetes mellitus. Results from a randomized study. *Acta Obstet Gynecol Scand.* 2000 Aug;79:649-54.
11. Ferrazzi EM, Frigerio L, Cetin I, et al. COVID-19 Obstetrics Task Force, Lombardy, Italy: Executive management summary and short report of outcome. *Int J Gynaecol Obstet.* 2020;149:377-378. doi:10.1002/ijgo.13162

Table 1 Maternal and obstetric characteristics of 57 women with gestational diabetes and a concomitant COVID-19 infection.

	Maternal age (years)	Multiparous	BMI (kg/m ²)	GD Therapy	Ethnicity	Gestational age at COVID-19 diagnosis (weeks)	COVID-19 Symptoms	Covid therapy	Gestational age at deliver	Labour	Delivery	Neonatal BW (gr)	HL (cc)	Apgar at 5 min	Analgesia	Breast feeding	Radiological signs	Days of hospitalization
1	32	Yes	24	Insulin	Caucasian	38+0	No	Heparin	39+1	Induced	Vaginal	3670	100	10	Epidural	No	No	6
2	26	Yes	30	Diet	Magreb	38+0	No	Heparin, hydroxychloroquine, azithromycin, oxygen	39+2	No labour	Elective CS	3000	400	10	Spinal	No	Yes	7

3	27	Yes	29	Diet	Magr eb	33+1	Fever	Heparin, hydroxyc hloroquin e	39+1	Indu ced	Vagi nal	375 5	60 0	10	Epidu ral	Yes	No	6
4	37	Yes	29	Diet	Hispa nic	39+0	Disp nea	Heparin, hydroxyc hloroquin e, azithromy cin, oxygen	39+2	No labo ur	Elec tive CS	339 5	20 0	10	Spina l	No	Yes	11
5	32	No	30,5	Diet	Magr eb	29+1	Fever	Heparin, oxygen	37+2	No labo ur	Elec tive CS	209 5	20 0	10	Spina l	No	No	49
6	40	Yes	31	Insuli n	Cauc asian	27+1	Fever	Heparin	38+2	No labo ur	Elec tive CS	364 0	50 0	10	Spina l	Yes	No	7

BMI: body mass index; GD: gestational diabetes; BW: birth weight; HL: blood loss at delivery.